Genetic Toxicology Testing Market: Introduction
Genetic testing can help determine a person’s risk of developing various types of cancer during their lifetime. Genetic testing is available to check for inherited variants and mutations in the DNA sequence that can lead to excessive cell growth and tumor/cancer formation. Examples include genetic testing to identify PALB2 (linked to increased risk of breast and pancreatic cancer), CHEK2 (breast and colon cancer), BRIP1 (ovarian cancer), and RAD51C and RAD51D (ovarian cancer).
That Genetic Toxicology Testing Market was worth about $7,836M in 2020 and is expected to generate $14,227M by 2026 at a CAGR of 10.45% over the forecast period.
Global Genetic Toxicology Testing Markets: Key Trends
The primary goal of R&D is to improve the chances of approval of phase I drug candidates by increasing the acceptance of active ingredients in the preclinical phase. In order to achieve this, intensive R&D activities are already carried out in the early stages of drug development. Consequently, the demand for genotoxicological services is increasing. Increased R&D spending in the early stages of drug development is expected to encourage the use of in vivo toxicology methods before a drug enters the costly clinical phase. This increases the demand for genotoxicology services, which further boosts the market.
Based on application, genotoxicology testing market is segmented into healthcare industry (pharmaceutical & biotechnology), food industry, cosmetics industry and others (agriculture and chemical industry). The cosmetics industry segment is expected to grow significantly over the forecast period. The increasing use of cosmetics due to rising disposable incomes and their widespread availability has prompted the industry to invest in breakthrough product research and development, which is expected to propel the market.
Get the report brochure @
